Bank of Nova Scotia Trims Stake in DexCom

Medical device company's shares sold by major investor

Mar. 17, 2026 at 7:24am

Got story updates? Submit your updates here. ›

Bank of Nova Scotia, a major investor in DexCom, Inc., has trimmed its stake in the medical device company by 4.9% during the third quarter, according to a recent SEC filing. The fund now owns approximately 504,913 shares of DexCom's stock, valued at around $33.975 million.

Why it matters

DexCom is a leading manufacturer of continuous glucose monitoring (CGM) systems, which are important tools for managing diabetes. The trimming of a major investor's stake could signal changing sentiment around the company's prospects, which is noteworthy given DexCom's prominent position in the CGM market.

The details

According to the SEC filing, Bank of Nova Scotia sold 25,742 shares of DexCom during the third quarter, reducing its total stake to 504,913 shares. This represents approximately 0.13% ownership of the medical device company. The filing does not provide specific reasons for the stake reduction.

  • The stake reduction occurred during the third quarter of the year.

The players

Bank of Nova Scotia

A major Canadian financial institution and one of DexCom's institutional investors.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Bank of Nova Scotia's stake in DexCom, while relatively small, could signal a shift in investor sentiment around the medical device company. Investors will likely be watching to see if other major institutional holders make similar moves, which could impact DexCom's stock price and market position going forward.